19 Feb 2019 14:09
Instem plc("Instem" or the "Company")
Director/PDMR Shareholding
Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, was notified on 19 February 2019, that the DG 2008 Discretionary Settlement (of which David Gare, Company chairman, and his wife are the trustees) transferred 100,000 ordinary shares of 10p each in the Company ("Ordinary Shares") to David's son, Adrian Gare, for nil consideration. Following the transaction, the DG 2008 Discretionary Settlement now has a total interest in 1,158,427 Ordinary Shares, representing approximately 7.28% of the Company's issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
a)
| Name
| David Gare and his wife (via the DG 2008 Discretionary Settlement)
| |||
2 | Reason for the notification | ||||
a)
| Position/status | Chairman of the Company | |||
b)
| Initial notification /Amendment | Initial | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a)
| Name
| Instem plc | |||
b)
| LEI
| 213800PILYUFNNROQX68 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 10p each | |||
Identification code | GB00B3TQCK30 | ||||
b)
| Nature of the transaction | Transfer of ordinary shares | |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
0p | 100,000 | ||||
d)
| Aggregated information | ||||
- Aggregated volume | N/A | ||||
- Price | |||||
e)
| Date of the transaction | 19 February 2019 | |||
f) | Place of the transaction | London Stock Exchange (XLON) | |||
For further information, please contact:
Instem plc | +44 (0) 1785 825 600 |
Phil Reason, CEO | |
Nigel Goldsmith, CFO | |
N+1 Singer (Nominated Adviser & Broker) |
+44 (0) 20 7496 3000 |
Richard Lindley Rachel Hayes | |
Walbrook Financial PR |
+44 (0) 20 7933 8780 |
Paul Cornelius | instem@walbrookpr.com |
Nick Rome Sam Allen
| |
About Instem
Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.
Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.
Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.
To learn more about Instem solutions and its mission, please visit instem.com.